Abstract: The present invention generally relates to the field of probiotic bacteria. In particular, it relates to methods for treating or preventing functional GI disorders comprising administering Bifidobacterium longum, such as Bifidobacterium longum ATCC BAA-999.

Abstract: The present invention relates generally to the field of biomarkers. The biomarker identified in the present invention is phenol. For example, the present invention relates to the use of phenol as a biomarker for detecting and/or quantifying mood disorder, improvements of the mood disorder status and/or the resulting emotional reaction of a subject. Embodiments of the resent invention relate to a method of detecting and/or quantifying mood disorder, improvements of the mood disorder status and/or the resulting emotional reaction of a subject, comprising determining the level of phenol in a body sample obtained from a subject to be tested, and comparing the subject's phenol level to a predetermined reference value, wherein a decreased phenol level in the sample compared to the predetermined reference value indicates an improvement of the mood disorder status and/or the resulting emotional reaction of the subject.

Abstract: The present invention relates generally to the field of biomarkers. The biomarker identified in the present invention is 2-methylbutyrate. For example, the present invention relates to the use of 2-methylbutyrate as a biomarker for detecting and/or quantifying mood disorder and improvements of the mood disorder status and/or the resulting emotional reaction of a subject. Embodiments of the resent invention relate to a method of detecting and/or quantifying mood disorders, improvements of the mood disorder status and/or the resulting emotional reaction of a subject, comprising determining the level of 2-methylbutyrate in a body sample obtained from a subject to be tested, and comparing the subject's 2-methylbutyrate level to a predetermined reference value, wherein an increased 2-methylbutyrate level in the sample compared to the predetermined reference value indicates an improvement of the mood disorder status and/or the resulting emotional reaction of the subject.

Abstract: The application relates to compositions containing 2?-FL and DFL for use in a method of reducing pain and/or the perception of visceral pain in a non-infant human.

Abstract: Serpin protein producing Bifidobacterium longum subsp. longum and compositions thereof for use in inhibiting gluten digestion. Compositions comprising the serpin protein producing Bifidobacterium longum subsp. longum may be used to mitigate the effects of hidden gluten in individuals following a gluten free diet.

Abstract: The present invention concerns an edible ingredient providing a short chain fatty acid ratio in the gut such that acetate is n a ratio ranging from 70 to 80, propionate is in a ratio ranging from 2 to 8, butyrate is in a ratio ranging from 20 to 25 and wherein the sum of individual ratios for acetate, propionate and butyrate equals 100 to food compositions comprising such edible ingredient for use in the attenuation of stress response and/or prevention of chronic stress and of conditions thereby associated.

Abstract: Use of a sugar selected from lactose, fructose and raffinose, for increasing serpin expression in Bifidobacterium longum strain CNCM I-2618.

Abstract: The present invention relates to compositions comprising a mix of human milk oligosaccharides consisting of 2?-fucosyllactose and difucosyllactose, for use in the reduction of pain and/or perception of pain in an infant or in a young child. The compositions are particularly effective in the restoration of the sensitivity of the bi-directional pain transmission pathways in the gut-brain axis to normal levels. The compositions are in particular useful in reducing abdominal pain, such as pain associated with gastrointestinal discomfort, functional gastrointestinal disorders, and/or gastrointestinal diseases and consequently also contribute to reducing the crying periods and to improving the quality of sleep, the general quality of life, the mood, the playfulness, the temperament and/or the happiness of the infants and young children.

Abstract: The present invention generally relates to the field of probiotic bacteria. In particular, it relates to methods for treating or preventing functional GI disorders comprising administering Bifidobacterium longum, such as Bifidobacterium longum ATCC BAA-999.

Abstract: The present invention generally relates to the field of probiotic bacteria. In particular, it relates to methods for treating or preventing functional GI disorders comprising administering Bifidobacterium longum, such as Bifidobacterium longum ATCC BAA-999.

Abstract: Disclosed is a probiotic combination comprising B longum CNCM I-2618 and B lactis CNCM I-3446 and —optionally further comprising B. longum ATCC BAA-999 for the treatment or prevention of an allergic disorder, or for the treatment or prevention of a food intolerance.

Abstract: Disclosed is a probiotic combination comprising B. longum and B. lactis for the treatment or prevention of an inflammatory-related gastrointestinal disorder such as an inflammatory bowel disease.

Abstract: Use of a sugar selected from lactose, fructose and raffinose, for increasing serpin expression in Bifidobacterium longum strain CNCM I-2618.

Abstract: Compositions and methods use Bifidobacterium longum NCC3001 (ATCC BAA-999) to stabilize or improve mood, modulate excessive emotional distress, reduce anxiety, and/or reduce stress. In an embodiment, the composition can be administered daily for at least three weeks.

Abstract: Compositions and methods use Bifidobacterium longum NCC3001 (ATCC BAA-999) to treat or prevent a depressive symptom. Prolonged anti-depressive effects can continue after administration of the compositions is ended. Non-limiting examples of a depressive symptom which can be treated or prevented include depressed mood; sadness; anxiety; “empty” feelings; loss of interest or pleasure; irritability; restlessness; changes in appetite or weight; sleep disturbances; lack of or decreased energy; feelings of worthlessness; guilt; helplessness; anger and hostility; difficulty in thinking, concentrating, or making decisions; hopelessness; tiredness; fatigue; memory difficulties; tearfulness; brooding; phobias; excessive worry over physical health; sexual dysfunction; persistent physical symptoms that do not respond to treatment; and combinations thereof.

Abstract: Compositions and methods use Bifidobacterium longum NCC3001 (ATCC BAA-999) to treat or prevent a depressive symptom. Prolonged anti-depressive effects can continue after administration of the compositions is ended. Non-limiting examples of a depressive symptom which can be treated or prevented include depressed mood; sadness; anxiety; “empty” feelings; loss of interest or pleasure; irritability; restlessness; changes in appetite or weight; sleep disturbances; lack of or decreased energy; feelings of worthlessness; guilt; helplessness; anger and hostility; difficulty in thinking, concentrating, or making decisions; hopelessness; tiredness; fatigue; memory difficulties; tearfulness; brooding; phobias; excessive worry over physical health; sexual dysfunction; persistent physical symptoms that do not respond to treatment; and combinations thereof.

Abstract: Methods and uses of B. longum strain ATCC-999 for the treatment or prophylaxis of infant colic are disclosed.

Abstract: Compositions and methods use Bifidobacterium longum NCC3001 (ATCC BAA-999) to treat or prevent a depressive symptom. Prolonged anti-depressive effects can continue after administration of the compositions is ended. Non-limiting examples of a depressive symptom which can be treated or prevented include depressed mood; sadness; anxiety; “empty” feelings; loss of interest or pleasure; irritability; restlessness; changes in appetite or weight; sleep disturbances; lack of or decreased energy; feelings of worthlessness; guilt; helplessness; anger and hostility; difficulty in thinking, concentrating, or making decisions; hopelessness; tiredness; fatigue; memory difficulties; tearfulness; brooding; phobias; excessive worry over physical health; sexual dysfunction; persistent physical symptoms that do not respond to treatment; and combinations thereof.

Abstract: Compositions and methods use Bifidobacterium longum NCC3001 (ATCC BAA-999) to stabilize or improve mood, modulate excessive emotional distress, reduce anxiety, and/or reduce stress. In an embodiment, the composition can be administered daily for at least three weeks.

Abstract: The invention discloses a composition comprising at least one long chain polyunsaturated fatty acid, at least one probiotic and a mixture of oligosaccharides, said mixture containing at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease. Said bone disease is in particular osteomalacia, rickets, osteopenia or osteoporosis. Preferably the composition is a nutritional composition.